Noticias

Novo Nordisk's (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy continues to outpace its main competitor despite a slight weekly decline in prescriptions, according to Citi's latest tracking data. The bank's weekly prescription tracker, based on IQVIA data, showed Wegovy...

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

Recent performance snapshot for Novo Nordisk (NVO) With no single headline event driving the move, Novo Nordisk (NVO) has drawn attention after a mixed stretch for the stock, including a gain of about 10% over the past month alongside weaker longer term returns. See our latest analysis for Novo Nordisk. Recent trading paints a mixed picture, with the share price up about 10% over the past month yet down over longer horizons, including a year to date decline of 14.6% and a 1 year total...

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Novo Nordisk has cancelled a planned US$1.33b rare disease factory project in Odense and will instead convert the site into a warehouse. The decision affects local job expectations and reflects cost cutting and capital reallocation within the company. The shift comes as Novo Nordisk pursues regulatory and clinical progress on next generation anti obesity therapies. Novo Nordisk (CPSE:NOVO B), currently trading around DKK299.2, is making this change after a period of mixed share...

Can Novo Nordisk thrive under intense competitive pressures?

European equities traded in the US as American depositary receipts were sharply lower late Friday mo

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

For a decade, owning anything outside the S&P 500 felt like paying tuition to learn a lesson you already knew. International developed equities lagged, the dollar marched higher, and every diversification pitch sounded like an apology. That trade has flipped. Over the past year, Vanguard FTSE Developed Markets ETF (NYSEARCA:VEA) returned 34% against the S&P ... International Stocks Keep Crushing the S&P. This Cheap ETF Is How You Get In

Gregory Demopulos: Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer; Dr. Cathy Melfi, our Chief Regulatory Officer; and Dr. Steve Whitaker, Vice President of Clinical. After that, David will cover the financials in more detail and then we'll open the call for questions.

European equities traded in the US as American depositary receipts were moving higher late Thursday

Novo Nordisk (NYSE:NVO) is one of the cheap stocks to buy for the next 10 years. On May 13, Novo Nordisk presented new data from the OASIS 4 clinical trial at the European Congress on Obesity 2026, highlighting the effectiveness of the oral Wegovy pill (25 mg). The findings reveal that nearly one-third of participants […]

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

Moby summary of Omeros Corporation's Q1 2026 earnings call

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA. Chairman and Chief Executive

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 15 years by 17.52% on an annualized basis producing an average annual return of 29.58%. Currently, Novo Nordisk has a market capitalization of $208.88 billion. Buying $100 In NVO: If an investor had bought $100 of NVO stock 15 years ago, it would be worth $4,873.71 today based on a price of $47.12 for NVO at the time of writing. Novo Nordisk's Performance Over Last 15 Years Finally -- what's the point of all this? The key insight

First-quarter results indicated they have the momentum to do it.

The worst might be in the rearview mirror.

Novo Nordisk A/S (NYSE:NVO) presented new analyses from its phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 in Istanbul, highlighting the long-term weight loss potential and functional benefits of its oral obesity treatment, Wegovy pill. The company said adults treated with oral semaglutide 25 mg achieved clinically meaningful weight loss regardless of whether they experienced rapid early reductions in body weight. Early Responders Saw Greater Long-Term Weight Loss Accord

The European stock markets were trending higher in Wednesday trading as investors monitor President

LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr

This data could help support Novo in its bid to claw back market share taken by Eli Lilly in the obesity space.

Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez have been highlighted in this Investment Ideas article.

Novo Nordisk A/S (NYSE:NVO) said its first quarter of 2026 was marked by rapid uptake of its newly launched Wegovy pill in the U.S., continued expansion of its obesity franchise and a series of pipeline and regulatory milestones, even as adjusted sales declined because of lower realized prices. Chi

Novo Nordisk presented new data at the European Congress on Obesity on high dose Wegovy (semaglutide 7.2 mg) from the STEP UP and SELECT trials and a large real world study. The results show substantial and consistent weight loss for women across life stages, including menopause, alongside reductions in body fat. The data highlight additional benefits tied to cardiovascular and mental health, including reduced risks of heart attack, stroke, migraine, and depression in menopausal...

Healthcare stocks advanced late Tuesday afternoon, with the NYSE Healthcare Index and the State Stre